These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 37165196)

  • 1. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
    Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
    Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
    Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
    Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized mRNA Vaccine Immunogenic against PDAC.
    Cancer Discov; 2023 Jul; 13(7):1504. PubMed ID: 37163684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
    Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
    Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
    Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
    Front Immunol; 2021; 12():691605. PubMed ID: 34484187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
    Panni UY; Chen MY; Zhang F; Cullinan DR; Li L; James CA; Zhang X; Rogers S; Alarcon A; Baer JM; Zhang D; Gao F; Miller CA; Gong Q; Lim KH; DeNardo DG; Goedegebuure SP; Gillanders WE; Hawkins WG
    Cancer Immunol Immunother; 2023 Aug; 72(8):2813-2827. PubMed ID: 37179276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
    Bassani-Sternberg M; Digklia A; Huber F; Wagner D; Sempoux C; Stevenson BJ; Thierry AC; Michaux J; Pak H; Racle J; Boudousquie C; Balint K; Coukos G; Gfeller D; Martin Lluesma S; Harari A; Demartines N; Kandalaft LE
    Front Immunol; 2019; 10():1832. PubMed ID: 31440238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
    Kinkead HL; Hopkins A; Lutz E; Wu AA; Yarchoan M; Cruz K; Woolman S; Vithayathil T; Glickman LH; Ndubaku CO; McWhirter SM; Dubensky TW; Armstrong TD; Jaffee EM; Zaidi N
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
    Sonntag K; Hashimoto H; Eyrich M; Menzel M; Schubach M; Döcker D; Battke F; Courage C; Lambertz H; Handgretinger R; Biskup S; Schilbach K
    J Transl Med; 2018 Feb; 16(1):23. PubMed ID: 29409514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
    Lutz E; Yeo CJ; Lillemoe KD; Biedrzycki B; Kobrin B; Herman J; Sugar E; Piantadosi S; Cameron JL; Solt S; Onners B; Tartakovsky I; Choi M; Sharma R; Illei PB; Hruban RH; Abrams RA; Le D; Jaffee E; Laheru D
    Ann Surg; 2011 Feb; 253(2):328-35. PubMed ID: 21217520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity.
    Fan T; Xu C; Wu J; Cai Y; Cao W; Shen H; Zhang M; Zhu H; Yang J; Zhu Z; Ma X; Ren J; Huang L; Li Q; Tang Y; Yu B; Chen C; Xu M; Wang Q; Xu Z; Chen F; Liang S; Zhong Z; Jamroze A; Tang DG; Li H; Dong C
    Sci Adv; 2024 Oct; 10(41):eadn9961. PubMed ID: 39392882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
    Balachandran VP; Łuksza M; Zhao JN; Makarov V; Moral JA; Remark R; Herbst B; Askan G; Bhanot U; Senbabaoglu Y; Wells DK; Cary CIO; Grbovic-Huezo O; Attiyeh M; Medina B; Zhang J; Loo J; Saglimbeni J; Abu-Akeel M; Zappasodi R; Riaz N; Smoragiewicz M; Kelley ZL; Basturk O; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Gönen M; Levine AJ; Allen PJ; Fearon DT; Merad M; Gnjatic S; Iacobuzio-Donahue CA; Wolchok JD; DeMatteo RP; Chan TA; Greenbaum BD; Merghoub T; Leach SD
    Nature; 2017 Nov; 551(7681):512-516. PubMed ID: 29132146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
    Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
    Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
    Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
    Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.